Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galcanezumab - Eli Lilly and Company

Next Previous
Search
Drug Profile

Galcanezumab - Eli Lilly and Company

Alternative Names: Emgality; Galcanezumab-gnlm; LY-2951742

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Analgesics; Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cluster headache; Migraine
  • No development reported Fibromyalgia
  • Discontinued Musculoskeletal pain

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for clinical-Phase-Unknown development in Fibromyalgia in Unknown
  • 22 Apr 2023 Efficacy and adverse events data from a phase III PERSIST trial in Migraine presented at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)
  • 27 Feb 2023 Eli Lilly has patent protection for galcanezumab in major European countries until 2033

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top